BMP and CMP Do Not Require Fasting
Neither the Basic Metabolic Panel (BMP) nor the Comprehensive Metabolic Panel (CMP) require fasting for routine clinical use. The components of these panels—including electrolytes, kidney function markers (creatinine, BUN), and glucose—can be reliably interpreted from non-fasting samples in most clinical scenarios.
Key Components and Fasting Considerations
Electrolytes and Kidney Function Markers
- Sodium, potassium, chloride, bicarbonate, creatinine, and BUN are not significantly affected by fasting status
- These can be drawn at any time of day without dietary restrictions
- Prolonged fasting (beyond overnight) shows statistically significant but not clinically significant changes in these parameters 1
Glucose Measurement
- Random (non-fasting) glucose is clinically useful and increasingly preferred for screening and monitoring 2
- Non-fasting glucose captures real-world glycemic exposure and can detect early metabolic dysfunction
- Fasting glucose remains important for specific diagnostic situations (formal diabetes diagnosis, impaired fasting glucose evaluation)
- If random glucose is elevated (>200 mg/dL with symptoms, or >125 mg/dL on screening), then fasting confirmation may be warranted
Lipid Components (in CMP)
While the standard BMP doesn't include lipids, if lipid parameters are part of an extended metabolic panel:
- Non-fasting lipid panels are acceptable for initial screening 3
- Total cholesterol, HDL-C, LDL-C, and non-HDL-C show minimal clinically significant variation between fasting and non-fasting states
- Fasting is required when:
Practical Algorithm
For routine BMP/CMP ordering:
- No fasting required for standard clinical monitoring
- Order as non-fasting for convenience and patient compliance
- Document fasting status on requisition (hours since last meal, rounded to nearest hour) 5
When to specifically request fasting:
- Formal diabetes diagnosis workup (need fasting glucose)
- Elevated random glucose requiring confirmation
- Triglycerides previously elevated or suspected to be high
- Evaluating response to lipid-lowering therapy when triglycerides >1.50 mmol/L 5
Common Pitfalls to Avoid
Don't delay necessary testing waiting for fasting status—most clinical decisions can proceed with non-fasting results. The practical advantages of non-fasting samples (improved patient compliance, any-time-of-day collection, reduced burden on laboratories) outweigh the minimal differences in most analytes 3.
Be aware of pre-analytical variables that matter more than fasting status: IV fluid administration, hemolysis, sample handling time, and patient positioning during collection can cause more significant variations than fasting status 6.
For glucose interpretation specifically: Non-fasting glucose >200 mg/dL with symptoms is diagnostic for diabetes without requiring fasting confirmation. Random glucose 140-199 mg/dL warrants follow-up fasting testing 2.
The shift toward non-fasting metabolic panels reflects modern understanding that these tests provide clinically equivalent information while improving accessibility and patient-centered care 3, 5.